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A bone targeting nanosystem is reported here which combined magnetic contrast agent for Magnetic Resonance Imaging
(MRI) and a therapeutic agent (bisphosphonates) into one drug delivery system. This new targeting nanoplatform consists
of superparamagnetic γFe2O3 nanoparticles conjugated to 1,5-dihydroxy-1,5,5-tris-phosphono-pentyl-phosphonic acid (di-
HMBPs) molecules with a bisphosphonate function at the outer of the nanoparticle surface for bone targeting. The as-synthesized
nanoparticles were evaluated as a speciﬁc MRI contrast agent by adsorption study onto hydroxyapatite and MRI measurment.
The strong adsorption of the bisphosphonates nanoparticles to hydroxyapatite and their use as MRI T2∗ contrast agent were
demonstrated. Cellular tests performed on human osteosarcoma cells (MG63) show that γFe2O3@di-HMBP hybrid nanomaterial
has no citoxity eﬀect in cell viability and may act as a diagnostic and therapeutic system.
1.Introduction
Bisphosphonates exhibits a powerful binding aﬃnity to
bones and are routinely used for treatment in bone
resorption and other bone disorders like Paget’s disease,
osteoporosis, or tumor induced osteolysis [1]. The binding
to bone mineral depends upon the P-C-P structure and is
enhanced by including a hydroxyl group (hydroxy methy-
lene bisphosphonate, called HMBP in the text). This was
probably due to tridendate binding hydroxyl substituted
bisphosphonates to calcium. In contrast, bisphosphonates
lacking a hydroxyl group, that provide a bidendate binding
to calcium crystals, had signiﬁcantly lower binding aﬃnities
[2].HenceHMBPmolecules,suchasAlendronate(4-amino-
1-hydroxybutylidenebisphosphonicacid),inhibitosteoclast-
mediated bone resorption [3]. With the recent developments
in magnetic resonance, in vivo studies showed that patients
with, and without, osteoroporotic fractures could better be
separated with parameters of bone architecture obtained
by MRI than BDM [4]. For molecular imaging, the use of
nanoparticles emerge as very exiting nanoobjects in that
many functionalities can be added to the surface of the
particle. More speciﬁcally, superparamagnetic iron oxide
[5] (SPIO, hydrodynamic diameter >50nm) and ultrasmall
superparamagneticironoxide(USPIO,hydrodynamicdiam-
eter <50nm) particles have been introduced as an MRI
contrast agent after the gadolinium chelates and appear
to be currently a more relevant agent than Gd chelates
due to the high MR signal per unit of metal. As these
particles are made of thousands iron atoms, they defeat the
inherent low contrast agent sensitivity of MRI and thus can
be detected at micromolar concentration of iron. Moreover
the iron ions are much less toxic than the gadolinium
ones and can be reused or recycled by cells using normal2 Journal of Osteoporosis
biochemical pathways for iron metabolism [6, 7]. Our
previous studies have shown that bisphosphonate such as 1-
phenyl-1-hydroxymethylene-1,1-phosphonic acid (HMBP-
COOH) [8] or 1-hydroxy-2-(imidazol-1-yl)ethylidene-1,1-
bisphosphonic acid (zoledronate) [9]a c ta sv e r ye ﬃcient
ligand for iron oxide nanoparticles. In the case of quaternary
ammonium bisphosphonate coated iron oxide nanocrystals,
it has been shown that this hybrid nanocrystals [10]
presented adequate performance for blood remanance and
weak liver capture. No signiﬁcant desorption of the coating
molecules was observed on steel plates. In recent work
[11] it has been demonstrated that pretreatment of metal
alloysurfacewithanaqueouspolyallylaminebisphosphonate
solution (BP-...NH2) result in the formation of a molecular
bisphophonate layer that permit the attachment via the
amine terminated function of vector binding agent for
therapeutic gene delivery. After 30 day incubation, the layer
is not altered indicating that a mechanism of desorption
reabsorption of BP molecules seems to be highly unlikely.
In this article, an innovative approach is presented, leading
to the optimization of the nanoparticle structure to achieve
selective targeting for osteoporosis imaging and therapy.
Superparamagneticnanoparticlesurfacearepassivatedusing
a bifunctional passivating agent such as 1,5-dihydroxy-1,5,5-
tris-phosphono-pentyl-phosphonic acid (call di-HMBP in
the text, Scheme 1). One HMBP function complexes the
nanocrystal surface and the other one at the outer surface
allows bone targeting. A stable ferroﬂuid (γFe2O3@di-
HMBP) is obtained on large concentration and pH range.
The large numbers of HMBP functionalities on the magnetic
core of the particle have a strong aﬃnity for hydroxyapatite
and can be used for bone targeting. The feasibility of such
process is demonstrated by the complexation of the hybrid
nanomaterialtocalciumionsandhydroxyapatiteandimaged
using MRI.
2.MaterialsandMethods
2.1. Materials and Reagent. IR spectra were recorded on
a Thermo Electron Corporation Nicolet 380 FTIR (KBr
pellet).UV-visiblespectrawererecordedonaVarianCary 50
Scan UV-Visible spectrophotometer. Transmission electron
microscopy (TEM) measurements were carried out using
a Philips CM10. 1H-NMR spectra were obtained on a
VarianGeminispectrometerat200MHzwithchemicalshifts
being reported as ppm from trimethylsilane as internal
standard. The size and the zeta potential of the nanocomplex
were determined by dynamic laser light scattering (DLS)
on a Nano-ZS (Red Badge) ZEN 3600 device (Malvern
Instruments, Malvern, UK. All chemicals products used for
nanoparticlesandbisphosphonatemoleculeswerepurchased
from Sigma-Aldrich (St Louis, MO). Millipore H2Ow a s
employed for the preparation of all aqueous solutions.
2.2. Synthesis of (1,5-Dihydroxy-1,5,5-Tris-Phosphono-Pen-
tyl)-Phosphonic Acid [12] (Di-HMBPs). In a 50mL round-
bottom three-neck ﬂask equipped with a thermometer,
glutaryl chloride (18mmol) was added dropwise, under
argon, at −5◦C, to tris(trimethylsilyl) phosphite (72mmol).
When addition wascompleted, reaction mixture wasallowed
to stand at room temperature for 1 hour. The evolution of
the reaction was monitored by 31P{1H} NMR. Then, volatile
fractions were evaporated under reduced pressure (0.1Torr)
before methanolysis (20mL). After evaporation, crude prod-
ucts were precipitated in diethylether and lyophilized. The
pure product was obtained in 95% yield. 31PN M R{1H}
(161.9MHz, D2O) δ 19.3, 1H NMR (400.1MHz, D2O) δ
1.78–2.05 (m, 6H, C(OH)-(CH2)3-C(OH)), 13CN M R{1H}
(100.6MHz, D2O) δ 18.1 (-CH2-CH2-CH2-), 34.0 (-CH2-
CH2-CH2-), 73.2 (t, 1JP−C = 143.7Hz, P-C(OH)-P).
2.3. Synthesis of γFe2O3@Di-HMBP Nanocrystals. To
prepare noncoated γFe2O3 particles, the ﬁrst step is
to add a solution of dimethylamine 40% in water
((CH3)2NH,10.5mL) to an aqueous micellar solution
of ferrous dodecyl sulfate (Fe(DS)2) (0.61g, 10
−3 mol). The
solution is stirred vigorously for 2 hours at 28.5
◦C and the
resulting precipitate of uncoated nanocrystals is isolated
from the supernatant by centrifugation. In the second step,
this precipitate is washed with an acidic solution (HCl
10−1 mol · L
−1) and a solution of di-HMBPs molecules
(n = 10
−4 mol in 30mL of water) is added. The solution is
stirred for two hours at room temperature. The precipitate
that appears is washed with an acidic solution (HCl
10−1 mol · L
−1). Free HMBP are isolated from the coated
particles thanks to a magnetic ﬁeld and by centrifugation.
The magnetic nanocrystals coated with di-HMBP molecules
are dispersed in water. The initial pH is equal to 4 and then
progressively increased to pH 7.4 by addition of sodium
hydroxide NaOH (10−1mol·L
−1). The iron concentration is
deduced from UV-vis absorption.
2.4. Nanocrystal Surface Characterization. FTIR spectro-
scopy is used to demonstrate nanocrystal surface com-
plexation via phosphonate groups. The average number
of molecules per nanocrystal is deduced with 31PN M R
spectroscopy. A range of concentrations of free di-HMBP
(NMR 31P{1H} (80.9MHz): 19.17ppm solution added with
NaH2PO4 (in capillary, 10−1 mol · L
−1;N M R31P{1H}
(80.9MHz): 0ppm) was prepared for calibration. The
di-HMBP molecules are removed from magnetic γFe2O3
nanoparticles by addition of sodium hydroxide NaOH
(1mol · L
−1) in order to avoid shifting of the 31PN M R
signal. The supernatant is analyzed with 31P NMR and the
concentration (number of molecules per nanocrystal) of di-
HMBP into the sample is deduced from this calibration plot.
2.5. Analysis of the Size and Surface Charges of the
γFe2O3@Di-HMBP Nanocrystals. The mean particle size
was determined by transmission electron microscopy. Col-
loid suspensions were deposited directly onto a carbon-
coated copper grid. The size and the zeta potential of
the nanocomplex was determined by dynamic laser light
scattering (DLS) on a Nano-ZS (Red Badge) ZEN 3600
device(MalvernInstruments,Malvern,UK.EachsamplewasJournal of Osteoporosis 3
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Scheme 1: Superparamagnetic γFe2O3@di-HMBPs for bone target-
ing.
analyzed at room temperature with diluted ferroﬂuid ([Fe] =
5 ·10
−4mol ·L
−1)a tp H= 7.4.
2.6.CalciumComplexometricTitration. Standardprocedures
with Eriochrome black T (EBT) was used to quantify the
amount of calcium ions in solution. The EBT was mixed
to γFe2O3@di-HMBP (or free di-HMBP) aqueous solution
([Fe] = 1,47 · 10
−2mol · L
−1) at pH 10. Then this solution
is titrated with calcium solution ([Ca2+] = 1,44 · 10
−4mol ·
L
−1) until the color solution change from blue to pink for
free di-HMBP and from green to brown for γFe2O3@di-
HMBP particles solution. The variation of color is due to
the complexation between EBT and calcium ions. Then
the amount of calcium ions complexed with the HMBP
functionality is deduced.
2.7. Magnetic Properties and Magnetic Resonance Imaging.
The magnetic behavior of the as-synthesized nanoparticles
is characterized using the MIAplex
R reader (Magnisense).
The MIAplex reader [13] measures the nonlinear response
of the magnetic labels when they are exposed to a multi-
frequency alternating magnetic ﬁeld. This speciﬁc signature
[14]i sb a s e do nd
2B(H)/dH2.
MRimagingofthetesttubeswasperformedusinga4.7T
MR scanner (Bruker). For measurements of T1 relaxation
times, axial spin echo (SE) sequences were obtained with
TR values of 10,000ms as well as TE of 16ms at 4.7T. For
measurements of T2∗ relaxation times, axial T2∗-weighted
SE images were obtained with a TR of 800ms and TE of
6.4ms at 4.7T.
2.8. In Vitro Hydroxyapatite Targeting. The lyophilized
hydroxyapatite [15] with a ratio Ca/P equal to 1,64. HA
(10mg/mL) was suspended in a 5 millimeter γFe2O3@di-
HMBP sol 0,4mg/mL (Fe = 5 · 10
−3 M). Then nanoparticles
are incubated and shaken with HA at 37
◦C during 24
hours. After ﬁltration and water washing with a syringe
ﬁlter with 0.45μm pore size, HA is resuspended in sol
and lyophilized for infrared spectroscopy. The concentration
of nanoparticles remained in the water suspension was
measured by UV/VIS spectrophotometer at 350 and 480nm
for the calculation of the amount bound to HA.
2.9. Cell Viability. Human osteosarcoma cells (MG63)
line was cultured in Dulbecco’s modiﬁed Eagle’s medium
(DMEM, Invitrogen) supplemented with 10% calf serum.
MG63 osteoblast-like cells used in the present study were
obtained from the American Type Culture Collection (ATCC
N
◦ CRL 1427).
Cell viability was evaluated using the MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
assay at day 1, day 3, and day 5. Cells were seeded at a density
of 20 × 103 cells/well in 96-well ﬂat-bottom plates (Falcon,
Strasbourg, France) and incubated in complete culture
m e d i u mf o r1 ,3 ,a n d5d a y s .T h e n ,m e d i u mw a sr e m o v e d
and replaced by 10% FCS-medium containing increasing
concentrations γFe2O3@di-HMBP nanocrystals. After 1, 3,
and 5 days of incubation, cells were washed with phosphate
buﬀered saline (PBS, Invitrogen) and incubated with 0.1mL
of MTT (2mg/mL, Sigma-Aldrich) for additional 4 hours at
37
◦C. The insoluble product was then dissolved by addition
of DMSO (Sigma-Aldrich). Optical density was measured at
570nm using a Labsystems Multiscan MS microplate reader.
Each in vitro experiment was performed three times, with
four wells per sample per experiment.
2.10. Cell Labelling. The labeling of living cells is evalu-
ated using Prussian blue staining for γFe2O3@di-HMBPs
nanocrystals. The principle of Prussian blue staining is that
the ferric iron (Fe3+) in the presence of ferrocyanide ion is
precipitated as the highly colored and highly water-insoluble
complex, potassium ferric ferrocyanide, Prussian blue. The
cellswerecultivatedfor24hoursineight-wellchamberslides
in the presence or not of γFe2O3@di-HMBPs nanocrystals.
The cells were then washed three times with PBS, ﬁxed with
acetone (10 minutes) and dried at room temperature for
20mn. The attached cell monolayer was incubated with 5%
potassium ferrocyanide (5 minutes), washed with PBS and
thenincubatedagainwithsolutioncontaining5%potassium
ferrocyanide and 10% hydrochloric acid for 10 minutes and
washed with distilled water three times. The iron particles
in the cells were observed as blue dots using an optical
microscope with phase contrast.
3. Results and Discussion
Nanoparticles functionalization plays a major role within
nanotechnologies applications. Scheme 1 describes the pro-
cedure to design a new MRI nanoparticle for targeted
drug delivery to bone. Small γFe2O3 nanocrystals were
chosen for their superparamagnetic behavior and their high
T2 contrast agent sensitivity for MRI. The 1,5-dihydroxy-
1,5,5-tris-phosphono-pentyl-phosphonic acid (di-HMBPs)
was chosen for the two HMBP functionalities: one HMBP
moiety as anchoring agent for γFe2O3 surface and the
second as targeting function due to strong aﬃnity for
bone. Our approach requires the two HMBP functions of4 Journal of Osteoporosis
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Figure 1: IR spectra of di-HMBP free molecules (blue curve)
and γFe2O3@di-HMBP (red curve). Insert: transmission electron
microscopy image taken of a nanoparticle solution at pH 7.
the molecule to be separated by a short spacer, to avoid
the nanoparticles anchoring with the two HMBP moieties,
leading to nanoparticles aggregation and lost of the speciﬁc
bone targeting.
Maghemite γFe2O3 nanocrystals were prepared as
described previously [16] by soft chemistry. At the end of
the synthesis, a solution of di-HMBP in water at pH 4
is added to the bare nanoparticle dispersion. The pH was
then progressively increased to pH 7.4 by the addition of
sodium hydroxide NaOH, thus achieving a stable dispersion
of nanoparticles.
After dialysis, the dispersed solution is lyophilized. The
powder is easily dispersed in water and the nanoparticles sols
arestableoverabroadrangeofpH(4–12)andconcentration
(over 40wt%), in suitable ionic strength (<0.6mol·L
−1)a n d
in various biological buﬀers such as PBS and Hepes. The
TEM image (insert Figure 1) of deposited nanocrystals indi-
cates an average diameter and a polydispersity, respectively,
equal to 11nm and 20%.
IR spectroscopy analysis (Figure 1) shows that the phos-
phonate groups are highly interaction with the nanoparticle
surface.
For the free HMBP-COOH molecules (blue curve),
within the P–O stretching region (1200–900cm−1), the
spectrum exhibits two sharp peaks at 1172 and 900cm−1,
assigned to P=Oa n dP – O H ,r e s p e c t i v e l y[ 17]. The broad
band at 1071cm−1 is characteristic for the vibrational mode
for the PO3 group [18].
Comparing the γFe2O3@di-HMBP nanocrystals (red
curve) with the free di-HMBP solution (blue curve), the
large changes observed within the P–O stretching region
(1200–900cm−1) show that a strong interaction between the
phosphonate headgroup and the Fe2O3 surface is present.
These results are consistent with phosphonate binding to
the oxide surface [19] and we can suggest that the Fe atoms
within the particle surface are coordinated by oxygen atoms
from the phosphonate groups [20].
31P NMR titration is used in order to quantify the
average number of molecules per nanocrystal. An average
number of 2100 ± 100 di-HMBP molecules per nanoparticle
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Figure 2: γFe2O3@di-HMBP second derivative of the magnetiza-
tion recorded at pH 7.4, in H2O solutions.
is obtained, corresponding to 0.1 equivalent per Fe ions
(around 0.3 per surface Fe ions).
Dynamic light scattering was used to characterize zeta
potential and hydrodynamic diameter. This measurement
is an indication of surface charge on a particulate species,
which plays an important role in determining solution
stability,susceptibilitytoaggregationandprecipitationprob-
lems, as well as protein and cellular surface binding in vivo.
AtphysiologicalpH,theγFe2O3@di-HMBPsparticlesexhibit
a negative zeta potential (−54mV) and a hydrodynamic
diameter of 36nm suggesting the presence of few aggregates
(meancrystallinecoreof11nm).Thenegativechargesurface
suggests the presence of free HMBP functionalities on the
magnetic core of the particle (Scheme 1). To determine
the number of free HMBP, we used standard procedures
of colorimetric tests to deduce the number of calcium ions
complexed per γFe2O3@di-HMBPnanoparticles.Forfreedi-
HMBP molecules, we found 3.8 calcium ions complexed
per molecule meaning that each HMBP functionality may
complex about 2 calcium ions. The amount of calcium
ions complexed per nanoparticle is found equal to 3100
± 200. Considering that each HMBP functionality may
complex 2 calcium ions, an amount of 1550 free HMBP per
nanoparticle is deduced. This result is consistent with NMR
measurements leading to 2100HMBP per nanoparticle.
Hence, the free HMBP functionalities at the outer of the
nanoparticles surface should allow their bone targeting and
the increase of bone mineral density.
Themagneticpropertiesofthesenanoparticleshavebeen
studied using a MIAplex
R reader.
The second derivative of magnetization d
2B(H)/dH2
(Figure 2), presents one maxima and one minima with no
hysteresis loop. This speciﬁc magnetic signature is charac-
teristic of superparamagnetic behavior of particles with low
dipolar interaction [21]. This superparamagnetic behavior
allows to use these particles as contrast agent for MRI.
To investigate the MR signal enhancement eﬀects, the
aqueous as-prepared nanoparticles at diﬀerent Fe concen-
trations were measured on a 4.7 T MRI scanner. As shownJournal of Osteoporosis 5
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Figure 3 :( a )T 1w e i g h tM Ri m a g e sa n dT 2 ∗ weight MR images
of aqueous solutions of as-synthesized nanoparticles at diﬀerent
Fe concentrations; (b) T1 and T2∗ relaxation rates (1/T1, 1/T2∗)
plotted against the Fe concentration for the various aqueous
solutions.
in Figure 3(a),b o t hT 1a n dT 2 ∗ weighted images change
drastically in signal intensity with an increasing amount of
nanoparticles, indicating that as synthesized nanoparticles
generated MR contrast on both longitudinal (T1) and trans-
verse (T2∗) proton relaxation times weighted sequences.
Figure 3(b) shows the relaxation rates 1/T1 and 1/T2∗ as
a function of the iron concentration. The relaxation rates
varied linearly with the iron concentration, as expected. The
longitudinalr1 andtransverser2
∗ relaxivities(corresponding
to the slopes of the lines) are found to be 1.40FemM−1s−1
and 295FemM−1s−1, respectively. Such values for r1 and r2
∗
suggest that HMBP coated nanoparticles can act as both T1
and T2
∗ contrast agents taking into account their small size,
b u ts e e mt ob em o r ef a v o u r a b l ea sT 2
∗ contrast agents due
to their much larger r2
∗ value.
One of the factors that makes HMBP most potent BP
drugs is its high skeletal uptake and retention, which is
directly related to its aﬃnity towards hydroxyapatite [22]
(HA). To demonstrate the speciﬁc targeting of γFe2O3@di-
HMPBs nanocrystals to bone, standard in vitro assay
[12] were performed to demonstrate the strong aﬃnity
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Figure 4: IR spectra of HA (red curve) and HA incubated with
γFe2O3@di-HMBP (blue curve) for 24 hours and separated from
free nanoparticules. Insert: optical image taken from HA (a) and
HA incubated with γFe2O3@di-HMBP (b).
of those new MRI contrast agent with hydroxyapatite.
A γFe2O3@diHMBP sol ([Fe] = 5 · 10
−3 M) have been
incubated with HA at 37
◦C, and then separated and washed
using a 0.45μm ﬁlter. The binding capacity of the as-
synthesized nanocomplexes has been studied using UV-vis
and infrared (Figure 4) spectroscopies. As shown insert
Figure 4, the change of HA color from white to brown indi-
cates γFe2O3@di-HMBPs binds HA with very high aﬃnity
due to the high amount of iron nanoparticles within HA.
The concentration of nanoparticles remained in the water
suspension was measured by UV-vis spectrophotometer at
350 and 480nm for the calculation of the amount bound
to HA. The deduced bound amount is equal to 0.05 ±
0.01mg of nanoparticles per mg of HA (eq. 0.19mMHMBP
per mgHA). Figure 4 displays the IR spectrum of HA
(blue curve) and incubated HA with γFe2O3@diHMBP
nanoparticles (red curve).
T h eH As p e c t r u m( r e dc u r v e )e x h i b i t sd i ﬀerent bands
between 1250–600cm−1 that are characteristic of the P–O
stretching region within HA [10]. For the HA nanocomplex,
the analysis of the P–O stretching region is complicated due
tostrongbackgroundabsorbanceoftheHAmatrix(ν(PO4))
[23]. The HA incubated with γFe2O3@di-HMBP (blue
curve), the P–O stretching region is broadened compared to
initial HA. This is very diﬃcult to clearly assign this eﬀect.
Obviously, more experiments are needed to elucidate the
exact mechanism of nanoparticle surface bonding on HA.
The magnemite nanocrystals deduced from UV-vis spec-
troscopy and the brown color (insert Figure 4)o fi n c u b a t e d
HA with γFe2O3@di-HMBP nanocrystals are suggesting
selective interaction of the nanocomplex with HA and then
potential targeting to bone.
In order to assess cell viability we performed viability
tests on osteosarcoma MG-63 cells, a cancer line, but
a pertinent model to study eﬃciently the behavior of
osteoblastic cell line [24]. The as-synthesized nanocrystals
were incubated with MG63 osteosarcoma cells precultured
for 24 hours, 3 days and 5 days for various extra cellular6 Journal of Osteoporosis
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Figure 5: Optical blue prussian images of MG63 cells control (a)
and MG63 cells incubating 24 hours with γFe2O3@di-HMBPs at
100μM (b). Comparative eﬀects of γFe2O3@di-HMBPs on MG-63
osteoblast cells proliferation (c) for 24 hours, (red curve), 3 days
(blue curve) and 5 days (green curve).
iron concentrations up to 3mmol·L
−1 (1eq.mmol·L
−1 di-
HMBP).TheproliferationofMG63cellswasindicatedbythe
MTT assay as shown in Figure 5).
For the three times of incubation, MTT proliferation
assayshowednormalgrowthofosteoblastcells.Nocytoxicity
was observed. To determine the intracellular uptake of
γFe2O3@di-HMBPs nanocrystals, blue prussian imaging
was performed on human MG63 cells (Figures 5(a) and
5(b)). The iron particles into the cells were observed as
blue dots using an optical microscope with phase contrast
(Figure 5(b)). This picture indicates massive and uniform
internalization of nanocrystals within the cells. Hence, the
γFe2O3@di-HMBPs nanocrystals may act as a diagnostic and
therapeutic system. A full biological study is in progress to
understand the mechanism of such nanoparticles for osteo-
porosis treatment and diagnostic. The aim of this work is
to describe inﬂuences of nanoparticles on protein expression
patterns related to the diﬀerentiation and mineralization of
bone-forming cells, viability, remodeling of cell architecture,
cell adhesion, and assembly of extracellular matrix in human
normal cells.
4. Conclusion
A bone-targeted MRI contrast agent have been designed
with superparamagnetic nanoparticles and bisphosphonate
moieties. HMBP functionalities exhibits highly iron and cal-
cium complexing eﬀects. To test feasibility of such nanosys-
tem, this system have been complexed to hydroxyapatite to
demonstrate bone targeting and increasing bone mineral
density to reduce the incidence of major osteoporotic
fracture. Moreover, the superparamagnetic behavior of such
nanoparticle allows them to be used as MRI contrast agent in
order to improve the therapeutic diagnostic for osteoporosis.
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